Rhythm Pharmaceuticals (NasdaqGM:RYTM) presented new long term efficacy and safety data for setmelanotide in pediatric ...

Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide ...

The prevalence of obesity is steadily rising and has huge health and financial implications for society. Weight gain is due to an imbalance between dietary intake and energy expenditure and research ...

Your brain and body are deeply linked through the hypothalamic-pituitary-adrenal (HPA) axis, a hormonal system that manages stress and influences memory. When cortisol levels stay balanced, it ...

First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity ---- European Commission grants authorization in adults ...

Please provide your email address to receive an email when new articles are posted on . Setmelanotide was linked to reduction in BMI at 52 weeks compared with placebo for patients with acquired ...

Obesity associated with hypothalamic dysfunction was initially described in patients with craniopharyngioma. Hypothalamic obesity may also result from brain radiation, infection (eg, tuberculosis), ...

Please provide your email address to receive an email when new articles are posted on . Participants receiving setmelanotide had a 19.8% greater BMI decrease than those assigned placebo at 1 year.

Findings showed patients on setmelanotide saw a mean BMI reduction of 16.5% from baseline compared with a 3.3% increase for those on placebo at week 52. Topline data were announced from a phase 3 ...